Phase 1 Breast Cancer Trial, Recruiting NCT07401381 Sponsor: Rovi Pharmaceuticals Laboratories Condition: Breast Cancer
Back to Breast Cancer

Phase 1 Breast Cancer Trial, Recruiting

NCT07401381
Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women who weigh at least 50 kg and have a Body Mass Index (BMI) between 19 and 39.
  • Women who have gone through menopause.
  • Women who have been diagnosed with a specific type of early-stage breast cancer (HR+/HER2- or HR+/HER2+), have finished at least 5 years of hormone-blocking treatment, and at least 2 of those years involved a medicine called letrozole — or, for women considered by their doctor to be at low risk of the cancer returning, at least 4 years of hormone-blocking treatment with at least 2 of those years on letrozole.
  • Women who are generally in good health.
  • Women who have had a breast scan (such as a mammogram) within the past 12 months showing no signs of cancer, or who are willing to have one done before the trial starts.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a serious medical condition that is not well managed or stable.
  • People who have used certain hormonal treatments — including estrogen, progesterone, oral contraceptives, or related medications — in the 3 months before screening.
  • People currently using certain medicines that affect how the body processes drugs (specifically those that affect enzymes called CYP3A4 and CYP2A6) (confirm with trial site).
  • People who have been diagnosed with osteoporosis.
  • People who have a pre-existing heart or blood vessel (cardiovascular) condition.
  • People who have tested positive for hepatitis B, hepatitis C, or HIV.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 10 July 2026

Contact this trial

Phone: +34913756230

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Rovi Pharmaceuticals Laboratories
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
1 May 2028

Primary endpoints

Area under the concentration-time curve within a dosing interval at Steady-State (SS AUCtau)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 10 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov